OBJECTIVE -To examine prospectively the relationship between diabetes, glycemic control, and spirometric measures.
S
everal cross-sectional studies have shown that type 2 diabetes is associated with reduced lung function (1) (2) (3) . Although this relationship could be interpreted as demonstrating the damaging effects of diabetes on the lung (4), a small-scale Scandinavian prospective study has provided some evidence that reduced pulmonary function is present before type 2 diabetes is diagnosed (5) . This may mean that diabetes and impaired lung function share common pathophysiologic determinants rather than the lung being a target organ in diabetes. Consistent with this hypothesis, duration of diabetes has been found to have a much stronger negative correlation with spirometric measures than does metabolic control (2, 3) . There has, however, been no prospective evaluation of the interrelationship between type 2 diabetes, glycemic exposure, and lung function. Such studies have an added importance with the development of inhaled insulin preparations, the long-term pulmonary toxicity of which is yet to be established (6) . We have, therefore, measured lung function in a large community-based cohort of patients with type 2 diabetes and repeated spirometry in a subgroup of these patients an average of 7 years later.
RESEARCH DESIGN AND
METHODS -We studied participants in the Fremantle Diabetes Study (FDS), a prospective observational study of care, metabolic control, and complications in patients recruited from a postcode-defined community of 120,097 people in Western Australia. The FDS protocol was approved by the Human Rights Committee, Fremantle Hospital, and all patients gave witnessed informed consent to participation. Descriptions of recruitment strategies, demographic characteristics of the sample, methods of defining diabetes type, and details of identified but nonrecruited patients have been published elsewhere (7, 8) . Of 2,258 subjects identified in the catchment area between 1993 and 1996, 1,426 (63%) were recruited to the FDS and 1,294 had type 2 diabetes.
The present study involved follow-up of a total of 495 FDS patients with type 2 diabetes (38% of all FDS patients with type 2 diabetes) who underwent spirometry between May 1993 and September 1994. The baseline cross-sectional characteristics and lung function in a subset of 421 patients (86%) have been reported
previously (3), and we added an additional 74 FDS patients to this sample. All patients were of European ethnic background and were between 25 and 85 years of age. They had no self-reported history of respiratory illness and were not being treated for respiratory disease.
Clinical assessment
All FDS subjects underwent initial comprehensive assessment and were invited for subsequent yearly reviews until late in 2001. Each assessment comprised a comprehensive medical history and physical examination, automated biochemical analyses of fasting blood and urine samples, and other tests. The same assay methodology was used throughout the study for key measures, including HbA 1c .
Patients were classified as having coronary heart disease (CHD) if there was a self-reported history of myocardial infarction, angina, coronary artery bypass grafting, angioplasty, and/or definite/probable ischemic changes on Minnesota coding of baseline electrocardiography. Retinopathy, defined as at least one microaneurysm in either eye or worse, was assessed from direct and/or indirect ophthalmoscopy through dilated pupils and/or more detailed data in patients assessed for photocoagulation. Neuropathy was defined as a score of Ͼ2/8 using the Michigan Neuropathy Screening Instrument clinical portion (9) . Microalbuminuria or worse was defined as a urinary albuminto-creatinine ratio Ն3.0 mg/mmol.
Pulmonary function testing
Baseline spirometry was performed using a Vitalograph Model S bellows spirometer (Vitalograph, Buckingham, U.K.) (3) . Each subject provided at least three acceptable tracings, from which forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), vital capacity (VC), and peak expiratory flow (PEF) were measured. All values were corrected for body temperature, air pressure, and water saturation. Before analysis, spirometric data were normalized by both dividing by the square of the patient's height (10) and expressing them as a percentage of those predicted for age, sex, and height based on data from healthy nonsmoking Caucasian subjects aged 25-79 years for PEF (11) and 25-84 years for VC, FVC, and FEV 1 (12) .
Follow-up spirometry was performed between June 2000 and July 2001 in all available consenting patients from the original sample of 495. The same standardized protocol was followed (13) , except that a MicroLab 3300 spirometer (Micro Medical, Gillingham, Kent, U.K.) was used. This instrument calculated predicted values using the same equations as the Vitalograph machine (11, 12) . Both spirometers have been validated to American Thoracic Society Spirometry Standards.
Because the normative equations used by the two spirometers were derived from U.S. studies performed by Knudson and coworkers (11, 12 ) Ͼ20 years ago, we used lung function data obtained in 1994 -1995 from Busselton, a regional Western Australia population center (14, 15) , as a source of local contemporaneous percentage-predicted values. Spirometric measures from 565 male and 928 female Europid Busselton residents who had never smoked and had no asthma, bronchitis, wheeze, or dyspnea were used to derive predictive equations for FEV 1 and FVC based on age, sex, and height.
Death ascertainment
The Western Australia death register is part of the larger Western Australia Health Services Research Linked Database. In addition, hospital records and primary health care physician contact were used to provide as much information as possible relating to details of death of FDS patients. These sources provided mortality data from the beginning of the study to death or study end (January 2002).
Statistical analysis
The computer software SPSS for Windows (version 10.0; SPSS, Chicago, IL) was used for statistical analysis. Data are presented as proportions, means Ϯ SD, median (interquartile range), or geometric mean (SD range). Updated means were calculated from yearly values to provide a single measure of blood pressure and glycemic and lipid exposure during followup. For waist circumference, categories of normal, overweight, and obese were defined for men (using 94 and 102 cm as cut points) and women (80 and 88 cm cut points) (16) .
Comparisons of two related samples were performed using McNemar's test, paired Student's t test, or the Wilcoxon's signed-rank test. Comparisons of multiple independent samples were performed by 2 test, one-way ANOVA, or KruskalWallis with post-hoc pairwise comparisons by Fisher's exact test, the least significant difference test, or MannWhitney U test, respectively. To minimize Type I error, a significance level of 0.01 was used. Associations between measures of glycemic control and lung function were assessed using multiple linear regression. Cox proportional hazards modeling was used to identify predictors of all-cause mortality in the baseline cohort, with variables significant at P Ͻ 0.2 in the univariate analysis included. For multiple linear and Cox proportional hazards regressions, variables were entered and removed at P Ͻ 0.05 and Ͼ 0.10, respectively.
RESULTS

Baseline patient characteristics
Of the original 495 patients, valid follow-up spirometric data were available for 125 (25.3%). The 370 patients for whom follow-up data were not available comprised 102 (20.6%) who died and 268 (54.1%) who were unable or unwilling to reattend for annual FDS reviews. Baseline details of patients classified according to follow-up status are shown in Table 1 . The 102 patients who died were significantly older and had longer duration of diabetes than the 393 patients who were alive at study end (January 2002). They also had higher mean systolic blood pressure, greater prevalence of complications, and worse lung function. For the survivors, there were no significant differences between the 125 patients who were restudied and the 268 patients who were not restudied, except for shorter median duration of diabetes in the former group. At baseline, 29 of the 125 follow-up subjects (23.2%) had FEV 1 percentagepredicted values Ͻ70% and/or VC percentage-predicted value Ͻ80% without recognized respiratory disease.
Changes in glycemic control and pulmonary function during follow-up The 125 prospective study patients were followed for 7.0 Ϯ 0.5 years. Absolute and percentage-predicted lung function measures at baseline and follow-up are summarized in Table 2 . All four values decreased significantly. The mean rate of decrease was 68 ml/year (1.1% predicted/ year) for FVC, 71 ml/year (1.5% predict-ed/year) for FEV 1 , 84 ml/year (1.6% predicted/year) for VC, and 17 l/min per year (3.1% predicted/year) for PEF. The rate of decrease in lung function for each measure was associated with its baseline value (0.28 Ͻ r Ͻ 0.49 for absolute measures and 0.41 Ͻ r Ͻ 0.49 for percentagepredicted value; P Յ 0.002 in each case).
At both baseline and follow-up, the Busselton-derived percentage-predicted values were similar to the Knudson-derived values for FEV 1 (P Ն 0.47), but FVC values were lower (P Ͻ 0.001). However, the magnitude of the change in percentage predicted over time was similar for FVC and FEV 1 using the two different methods (P Ն 0.06).
When mean Knudson-derived percentage-predicted values for each measure were plotted against median duration of diabetes at each time point (see Fig. 1 ), linear extrapolation gave an intercept at 100% lung function of between 1.1 and 2.8 years before diagnosis. The equivalent Busselton-derived inter- Because the rate of decline in lung function was dependent on the baseline level, we investigated associations between glycemic control (updated mean and follow-up values of both fasting plasma glucose and HbA 1c ) and lung function at the end of follow-up (both absolute and percentage-predicted values) after adjusting for the baseline value and other potential confounding or explanatory variables. Three linear regression models were fitted sequentially: model 1, independent variables with a potential influence on followup lung function (baseline lung function, sex, follow-up age, BMI, duration of diabetes, and smoking status); model 2, variables listed in model 1, together with vascular risk factors (updated mean systolic and diastolic blood pressures and serum total cholesterol, HDL cholesterol, and triglyceride levels); and model 3, variables listed in model 2 plus presence or absence of complications at follow-up (CHD, microalbuminuria, neuropathy, and retinopathy). After controlling for the variables included in these three models, stepwise forward selection was performed to identify the measure of glycemic control with the strongest association with each lung function measure. This single index of glycemic exposure was then added back into the three models above.
For both height squared-normalized and percentage-predicted measures, there were consistent significant, negative associations with glycemic exposure in each model, in the form of either updated mean HbA 1c or follow-up HbA 1c or fasting plasma glucose (see Table 3 ). For the fully adjusted model, for example, an increase of 1% in updated mean HbA 1c was associated with a decrease of 4% in FVC percentage-predicted value. The FEV 1 -to-FVC ratio at follow-up was also significantly and negatively associated with follow-up HbA 1c (P ϭ 0.005).
Baseline predictors of mortality Significant univariate baseline predictors of mortality at study end (January 2002) in the whole cohort were older age, male sex, longer duration of diabetes, higher systolic blood pressure, retinopathy, neuropathy, micro-or macroalbuminuria, and CHD (P Ͻ 0.02), as well as each of the four percentage-predicted lung function measures (P Յ 0.001 in each case for both Knudson-and Busselton-derived values). The nonspirometric variables in this list, and two others (BMI and smoking status) significant at P Ͻ 0.2, were incorporated into a forward-conditional Cox proportional hazards regression model. After adjusting for each of these variables in the model and adding the spirometric measures, only the FEV 1 percentage-predicted value (hazard ratio [95% CI] 1.13 [1.02-1.26] for a decrease of 10%; P ϭ 0.025) was a significant independent predictor of allcause mortality. The findings when Busselton-derived percentage-predicted values were used were similar (data not shown).
CONCLUSIONS -T h e p r e s e n t study is the largest to have examined prospectively the relationship between diabetes and pulmonary function and the only one in patients with type 2 diabetes. We found that, relative to values predicted for age, sex, and height, each of FVC, FEV 1 , VC, and PEF decreased at an average of between 1.1 and 3.1%/year in our community-based cohort. FVC and FEV 1 decreased by means of 68 and 71 ml/year in absolute terms, rates that are approaching double those reported in prospective studies involving samples from the general population (Յ40 ml/ year) (10, 17) , including one from the Busselton study (15) . These data provide evidence that reduced lung volumes and airflow limitation complicate diabetes. Glycemic exposure (principally in the form of the updated mean or follow-up HbA 1c ) was a strong and consistent negative predictor of follow-up lung function after adjusting for baseline values and potential confounding or explanatory variables. Previous studies assessing the relationship between blood glucose control and pulmonary function have produced inconsistent results. Crosssectional associations between HbA 1c and spirometric measures were weak in our original study (3) and were not seen in the Rancho Bernado cohort (2). However, a large Danish cross-sectional population study (1) showed a negative association between plasma glucose and both FVC and FEV 1 . In a small-scale, 6-year study of patients with type 1 diabetes, intensive treatment by subcutaneous insulin infusion improved both FVC and FEV 1 percentage-predicted values, whereas those allocated to twice-daily premixed insulin had Ͼ15% mean reductions in these measures (18) . Thus, the only two prospective studies in diabetes have shown consistent results, albeit in different contexts.
Our study has limitations. First, the prospective study patients were healthy survivors. The percentage-predicted values of each spirometric measure at 5.0 years' duration of diabetes interpolated from our baseline and follow-up data were close to, but mostly greater than, those observed in the cross-sectional patients who were not followed and who had been diabetic for a median of 5.0 years. Second, because of the time between paired studies, we used two different spirometers and, despite validation to American Thoracic Society standards and the use of the same algorithms to generate percentage-predicted values, there may have been differences in performance. However, the potential discrepancies be- tween spirometric measures obtained by the two instruments (0 -5%) (19 -22) do not account for the significantly greater changes we found in our diabetic patients compared with those predicted. In addition, preliminary 3-year follow-up data from the Atherosclerosis Risk in Communities study (23) also show a more rapid decrease in diabetic versus nondiabetic individuals. Our data suggest that lung function measures start to decrease several years before diagnosis, consistent with similar estimates from studies of retinopathy progression (24) and preliminary longitudinal spirometric data from a small European cohort (5) .
Reduced spirometric measurements do not identify a specific underlying pathology, but there have been preliminary reports of histopathologic changes in the lungs of diabetic patients, including basal lamina thickening (25) and fibrosis (26) . Other possible contributory factors include glycation of chest wall/bronchial tree proteins (27, 28) , autonomic and/or phrenic neuropathy causing alterations in bronchial reactivity and respiratory muscle function (29) , and an increased propensity to, and severity of, respiratory infections (30, 31) . It is also possible that our spirometric data reflect the effects of chronic illness on effort-dependent measures, but duration of diabetes was not consistently associated with changes in lung function.
Several studies have found an association between impaired lung function and death (32) (33) (34) . We found that a 10% decrease in FEV 1 was associated with a 12% increase in all-cause mortality, a figure very similar to the 11-15% increase found in the general population (14, 35, 36) , including a report from Busselton (15) . This indicates that, despite the presence of other strong diabetesrelated causes of death, including CHD and microangiopathy, airflow limitation was an important predictor of mortality. This finding is consistent with Wisconsin Epidemiologic Study of Diabetic Retinopathy data showing an association between PEF and mortality (37) .
Our data support the suggestion that the lung is a target organ in diabetes and that glycemic exposure is a strong determinant of reduced pulmonary function in type 2 patients. Furthermore, because measures of airflow limitation predict allcause mortality in type 2 diabetes, intensive glycemic management may reduce the risk of death through improved ventilatory function independent of other beneficial effects. In the light of the development of inhaled insulin preparations, our data emphasize the importance of control groups in the assessment of pulmonary toxicity so the effects of glycemic exposure per se can be differentiated from those related to therapy.
